Form 4 for OGN Organon & Co.
Accepted 2026-04-02 16:06:14 ET · period of report 2026-03-31 · accession 0001628280-26-023139 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-04-02 16:06 | 2026-03-31 | OGN | Holzbaur Lynette | SVP, Corp. Ctrl | M - OptEx | $0.00 | +11.0K | 28.3K | +63% | $0 |
| DM | 2026-04-02 16:06 | 2026-03-31 | OGN | Holzbaur Lynette | SVP, Corp. Ctrl | F - Tax | $5.70 | -3,126 | 26.4K | -11% | -$17.8K |
| DM | 2026-04-02 16:06 | 2026-03-31 | OGN | Holzbaur Lynette | SVP, Corp. Ctrl | A - Grant | $0.00 | +116.9K | 41.7K | New | $0 |
| DM | 2026-04-02 16:06 | 2026-03-31 | OGN | Holzbaur Lynette | SVP, Corp. Ctrl | M - OptEx | $0.00 | -11.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-31 | M | A | 4,252 | $0.00 | 22,813.43 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-31 | F | D | 1,212 | $5.70 | 21,601.43 | D | — | — | (F1) The price is the closing market price for Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. |
| 3 | Common | Common Stock | 2026-03-31 | M | A | 6,715 | $0.00 | 28,316.43 | D | — | — | |
| 4 | Common | Common Stock | 2026-03-31 | F | D | 1,914 | $5.70 | 26,402.43 | D | — | — | (F1) The price is the closing market price for Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. |
| 5 | Derivative | Restricted Stock Units | 2026-03-31 | A | A | 75,125 | $0.00 | 75,125 | D | — · — to — | 75,125 Common Stock | (F2) On March 31, 2026, the Reporting Person was granted 75,125 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. (F2) On March 31, 2026, the Reporting Person was granted 75,125 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. (F2) On March 31, 2026, the Reporting Person was granted 75,125 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. |
| 6 | Derivative | Restricted Stock Units | 2026-03-31 | A | A | 41,736 | $0.00 | 41,736 | D | — · — to — | 41,736 Common Stock | (F3) On March 31, 2026, the Reporting Person was granted 41,736 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. (F3) On March 31, 2026, the Reporting Person was granted 41,736 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. (F3) On March 31, 2026, the Reporting Person was granted 41,736 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. |
| 7 | Derivative | Restricted Stock Units | 2026-03-31 | M | D | 4,252 | $0.00 | 0 | D | — · — to — | 4,252 Common Stock | (F4) Each RSU represents a contingent right to receive one share of Organon common stock. (F5) On March 31, 2023, the Reporting Person was granted 12,755 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. (F5) On March 31, 2023, the Reporting Person was granted 12,755 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. |
| 8 | Derivative | Restricted Stock Units | 2026-03-31 | M | D | 6,715 | $0.00 | 0 | D | — · — to — | 6,715 Common Stock | (F4) Each RSU represents a contingent right to receive one share of Organon common stock. (F6) On March 31, 2025, the Reporting Person was granted 20,147 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. (F6) On March 31, 2025, the Reporting Person was granted 20,147 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. |